Chondrosarcoma in the United States (1973 to 2003): an analysis of 2890Â cases from the SEER database.
(For the full paper see link below)
Background: Current demographic, prognostic, and outcomes data on theÂ diagnosis and treatment of chondrosarcoma have been based on case seriesÂ reported by individual treatment centers. The SEER (Surveillance,Â Epidemiology and EndÂ Results) database is a validated national epidemiological surveillanceÂ system and cancer registry that has been used extensively to evaluateÂ treatment outcomes in cases of malignancy. The purpose of the present studyÂ was to use this database to identify demographic and prognosticÂ characteristics of chondrosarcoma and to describe the natural historyÂ following the treatment of this rare disease in the United States over theÂ last thirty years.
Methods: Two thousand eight hundred and ninety patients with chondrosarcomaÂ were identified in the SEER database, and information regarding theÂ demographic and clinical characteristics of the patients, the histologicalÂ features and grade of the tumors, the location and size of the tumors, theÂ surgical stage at the time of diagnosis, the use of surgery and radiationÂ treatment, and survival were extracted.
Results: Comparison of the overall and disease-specific survival ratesÂ revealed that patients who survived for ten years were more likely to die ofÂ events that were unrelated to chondrosarcoma. The disease-specific survivalÂ rate leveled off at ten years of follow-up. Univariate analysis revealedÂ that female sex, a low histological grade, and local surgical stage wereÂ associated with a significant disease-specific survival benefit. An age ofÂ fifty years or less and an appendicular location of the tumor wereÂ associated with a significant overall survival benefit. On multivariateÂ analysis, only grade and stage had significant association withÂ disease-specific survival. On the basis of a comparison of survival ratesÂ according to the decade of diagnosis, it appears that there has been noÂ significant improvement in survival over the last thirty years.
Conclusions: Only grade and stage are independent prognostic factors forÂ survival in cases of chondrosarcoma. Current treatment algorithms have notÂ improved the survival rates of patients with chondrosarcoma over the pastÂ thirty years.Â Routine patient surveillance following treatment should be extended to tenÂ years of follow-up.Â